A Study of Invikafusp Alfa (STAR0602), a Selective T Cell Receptor (TCR)-Targeting, Bifunctional Antibody-fusion Molecule, in Combination With Sacituzumab Govitecan in Participants With Advanced Solid Tumors
PHASE1
This is a Phase 1b/2, Open-label Study to Investigate the Safety and Effica...
Treatment for Advanced Non-small Cell Lung Cancer With Actionable Genomic Alterations After Targeted Treatment and Chemotherapy (An Expanded Lung-MAP Treatment Trial)
PHASE2
This phase II Expanded Lung-MAP treatment trial compares how well sacituzum...
Clinical Outcomes and Safety of Sacituzumab Govitecan in Metastatic HER-2 n...
Status
Recruiting
Location
Fudan University Shanghai Cancer Center
Start Date
2024-08-12
Trial ID
NCT06966141
TREND-02 - a Phase II Exploratory De-escalation Trial of Neoadjuvant Sacituzumab Govitecan Plus Tislelizumab (SG/I) in Early Triple-negative Breast Cancer
PHASE2
Refining neoadjuvant chemoimmunotherapy and establishing predictive biomark...